Cherian Laurel, Cutting Shawna, Song Sarah
Section of Cerebrovascular Disease, Department of Neurology, Rush University Medical Center, 1725 W. Harrison Street, Suite 1121, Chicago, IL, 60612, USA,
Curr Cardiol Rep. 2015 Oct;17(10):82. doi: 10.1007/s11886-015-0639-z.
Intravenous thrombolysis is considered to be standard of care for acute ischemic stroke patients arriving within 3-4.5 h of stroke symptom onset. Recently, endovascular therapies have been proposed to extend and enhance stroke outcomes by targeting large vessel occlusions. Different radiologic methods, time windows, and treatment tools have delineated differences between trials. Overall, intravenous thrombolysis remains the treatment of choice for all acute ischemic stroke patients, with a small subset benefiting from additional endovascular therapy. Endovascular therapy remains a viable singular option for patients with large vessel occlusion unable to receive thrombolysis.
静脉溶栓被认为是卒中症状发作后3 - 4.5小时内就诊的急性缺血性卒中患者的标准治疗方法。最近，血管内治疗已被提出，旨在通过针对大血管闭塞来扩大和改善卒中治疗效果。不同的影像学方法、时间窗和治疗工具在各试验之间划出了差异。总体而言，静脉溶栓仍然是所有急性缺血性卒中患者的首选治疗方法，一小部分患者可从额外的血管内治疗中获益。血管内治疗对于无法接受溶栓的大血管闭塞患者仍然是一种可行的单一治疗选择。
